Lamdong Pharmaceutical Joint Stock Company Sustainability Profile
Lamdong Pharmaceutical Joint Stock Company, commonly known as Ladophar, is a prominent player in the pharmaceutical industry, headquartered in Lam Dong Province, Vietnam. Established in 1983, the company has made significant strides in the production and distribution of high-quality pharmaceutical products, primarily focusing on generic medicines, herbal remedies, and dietary supplements. With a strong operational presence across Vietnam, Ladophar is recognised for its commitment to innovation and quality. The company’s core offerings include a diverse range of pharmaceuticals that cater to various therapeutic areas, setting them apart through rigorous quality control and adherence to international standards. Ladophar has achieved notable milestones, including certifications from global health authorities, which solidify its market position as a trusted provider in the Vietnamese pharmaceutical landscape.
DitchCarbon Score
How does Lamdong Pharmaceutical Joint Stock Company's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Lamdong Pharmaceutical Joint Stock Company's score of 20 is lower than 79% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Lamdong Pharmaceutical Joint Stock Company's reported carbon emissions
Lamdong Pharmaceutical Joint Stock Company, headquartered in Vietnam, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, the company has not established any documented reduction targets or climate pledges, which suggests a lack of formal commitments to address carbon emissions at this time. As there are no emissions data or reduction initiatives available, it is unclear how Lamdong Pharmaceutical aligns with industry standards for climate action. The absence of emissions reporting may reflect a broader trend within the pharmaceutical sector, where companies are increasingly being urged to disclose their environmental impact and set ambitious targets for carbon reduction. In summary, Lamdong Pharmaceutical Joint Stock Company has not provided emissions data or climate commitments, indicating a potential area for improvement in their sustainability practices.
How Carbon Intensive is Lamdong Pharmaceutical Joint Stock Company's Industry?
How Carbon Intensive is Lamdong Pharmaceutical Joint Stock Company's Location?
Lamdong Pharmaceutical Joint Stock Company's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Lamdong Pharmaceutical Joint Stock Company has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
